Shots:
- The P-IIIb STASEY study evaluates the safety of Hemlibra (qw for ~2 yrs.) in 193 patients with hemophilia A with factor VIII inhibitors. The results of the study are consistent with a P- III HAVEN program
- The results from the final analysis of a P-IIIb STASEY study showed no new thrombotic microangiopathy or thrombotic SAEs & no new safety signals were observed. The therapy showed effective bleed control with 82.6% of patients achieving zero treated bleeds
- Additionally, the study reinforced that Hemlibra is associated with a low incidence of ADA development. The therapy is approved to treat patients with hemophilia A with/out factor VIII inhibitor in 100+/80+ countries respectively
Click here to read the full press release/ article | Ref: Business Wire | Image: Center for Health Journalism
The post Genentech Reports New Data of Hemlibra (emicizumab-kxwh) in P-IIIb STASEY Study to Treat Hemophilia A first appeared on PharmaShots.
